Samsung and Verizon will exit social video app developer Rounds in a deal reportedly sized at between $60m and $80m.

AnaptysBio, which filed for the IPO in 2015, has gone public in an offering that will give long-term investor Novo an exit.

Novo and Merck Group have exited ObsEva in an offering that involved the reproductive health treatment developer floating in the middle of its range.

HD Biosciences, a contract drug research services provider backed by Pfizer and Eli Lilly, has been acquired by WuXi AppTec for an undisclosed sum.

Alphabet is set to exit programmatic advertising software provider Adelphic, which has agreed to an acquisition of undisclosed size by Time subsidiary Viant.

In 2016 GCV Analytics tracked 1,952 deals worth an estimated $83.59bn of total capital raised.

Versarien has purchased an 85% stake in Cambridge Graphene for $210,000 in stock and cash.

The reproductive health therapy developer, which has raised more than $93m from backers including Novo and Merck Group, has set the terms for its initial public offering.

Microsoft has acquired speech recognition specialist Maluuba for an undisclosed amount, providing investor Samsung Ventures with an exit.

Knightscope, backed by NTT Docomo, Konica Minolta and Flextronics, has opted for a regulation A+ offering that enables members of the public to buy shares.